{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:23:57Z","timestamp":1778084637324,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korean government (MSIT)","award":["RS-2023-00217123"],"award-info":[{"award-number":["RS-2023-00217123"]}]},{"name":"Korean government (MSIT)","award":["2022R1F1A1075439"],"award-info":[{"award-number":["2022R1F1A1075439"]}]},{"name":"Korean government (MSIT)","award":["HY-2025-1103"],"award-info":[{"award-number":["HY-2025-1103"]}]},{"name":"Research Fund of Hanyang University","award":["RS-2023-00217123"],"award-info":[{"award-number":["RS-2023-00217123"]}]},{"name":"Research Fund of Hanyang University","award":["2022R1F1A1075439"],"award-info":[{"award-number":["2022R1F1A1075439"]}]},{"name":"Research Fund of Hanyang University","award":["HY-2025-1103"],"award-info":[{"award-number":["HY-2025-1103"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: This study aimed to evaluate the risk of upper gastrointestinal (UGI) adverse events (AEs) associated with oral anticoagulants (OACs) and identify potential interactions with cardiovascular (CV) drugs. Methods: Individual case safety reports (ICSRs) from the FDA Adverse Event Reporting System from July 2014 to December 2023 were analyzed. Dataset I was constructed to assess the associations between OACs and UGI AEs using disproportionality analysis. Dataset \u2161 included OAC-related ICSRs to explore potential interactions with CV drugs through logistic regression. Positive signals were defined as potential associations identified by disproportionality analysis metrics, such as reporting odds ratios (RORs) or adjusted RORs (aRORs) accounting for confounders. Results: Dataset I included 12,905,290 ICSRs, and a positive signal for dabigatran was detected with an ROR of 1.19 (95% CI, 1.13\u20131.25). A total of 364,044 OAC-related ICSRs were included in dataset II. At the pharmacologic drug class level, several positive signals were identified, represented as aRORs with 95% CIs: for warfarin, amiodarone analogs (1.22; 1.04\u20131.43); for apixaban, angiotensin-converting enzyme inhibitors (1.34; 1.24\u20131.45), angiotensin receptor blockers (1.23; 1.14\u20131.33), dihydropyridine calcium channel blockers (1.30; 1.21\u20131.41), and digitalis glycosides (1.72; 1.49\u20132.00); and for edoxaban, angiotensin receptor blockers (1.88; 1.48\u20132.37), amiodarone analogs (1.73; 1.06\u20132.85), and anti-platelets (1.56; 1.20\u20132.03). No signals were observed for rivaroxaban or dabigatran. At the individual drug level, 62 OAC-CV pairs were identified as having potential interactions. Conclusions: Drug-specific interaction profiles should be considered to ensure safe and personalized use of OACs in clinical practice.<\/jats:p>","DOI":"10.3390\/ph18091311","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:27:44Z","timestamp":1756733264000},"page":"1311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0952-3437","authenticated-orcid":false,"given":"Seunghyun","family":"Cheon","sequence":"first","affiliation":[{"name":"College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6871-1081","authenticated-orcid":false,"given":"Jiyeon","family":"Park","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dosol","family":"Oh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanyang University Hospital, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-1530","authenticated-orcid":false,"given":"Jee-Eun","family":"Chung","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11096-024-01832-9","article-title":"Exploring the association of adverse drug reactions with medication adherence and quality of life among hypertensive patients: A cross-sectional study","volume":"47","author":"Insani","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12876-024-03267-y","article-title":"The prevalence and severity of upper gastrointestinal complications among patients with chronic diseases: A cross-sectional study from Palestine","volume":"24","author":"Tumeh","year":"2024","journal-title":"BMC Gstroenterol."},{"key":"ref_3","unstructured":"Pitchumoni, C.S., and Dharmarajan, T.S. (2021). Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). Geriatric Gastroenterology, Springer. [2nd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","article-title":"Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism","volume":"41","author":"Witt","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012\u20132021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"(2025, July 11). FDALabel: Full-Text Search of Drug Product Labeling, Available online: https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e021765","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/pds.4684","article-title":"Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints","volume":"27","author":"Zielinski","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e071907","DOI":"10.1136\/bmjopen-2023-071907","article-title":"Oral anticoagulant switching in patients with atrial fibrillation: A scoping review","volume":"13","author":"Adelakun","year":"2023","journal-title":"BMJ Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2019.10.047","article-title":"Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry","volume":"125","author":"Paquette","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e13498","DOI":"10.1111\/eci.13498","article-title":"Integrated care and outcomes in patients with atrial fibrillation and comorbidities","volume":"51","author":"Proietti","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/jcph.2106","article-title":"Gastrointestinal Bleeding During Direct Oral Anticoagulant Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of Polypharmacy","volume":"62","author":"Honda","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11239-018-1738-7","article-title":"Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients","volume":"46","author":"Rottenstreich","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood-2023-184907","article-title":"Outcomes of Oral Anticoagulation with Concomitant NSAID Use: A Registry Based Cohort Study","volume":"142","author":"Schaefer","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4330\/wjc.v15.i8.375","article-title":"Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view","volume":"15","author":"Abrignani","year":"2023","journal-title":"World J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","article-title":"Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions","volume":"11","author":"Magro","year":"2012","journal-title":"Expert Opin. Drug. Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"923939","DOI":"10.3389\/fphar.2022.923939","article-title":"Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/14740338.2024.2376693","article-title":"Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-024-00738-6","article-title":"Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use","volume":"25","author":"Honma","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sridharan, K., and Sivaramakrishnan, G. (2025). Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041097"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: An example with diuretics and non-steroidal anti-inflammatory drugs","volume":"56","author":"Egberts","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40801-023-00362-6","article-title":"Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database","volume":"10","author":"Kobayashi","year":"2023","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10787-007-1578-0","article-title":"Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs","volume":"16","author":"Chiba","year":"2008","journal-title":"Inflammopharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/eurheartj\/eht307.P549","article-title":"Management of dyspepsia symptoms on dabigatran during RELY-ABLE: Long-term follow up study after RE-LY","volume":"34","author":"Nieuwlaat","year":"2013","journal-title":"Eur. Heart. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2012.10.021","article-title":"Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial","volume":"11","author":"Bytzer","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/14740338.5.4.585","article-title":"Drug-induced side effects affecting the gastrointestinal tract","volume":"5","author":"Leong","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/flgastro-2013-100316","article-title":"Drug-induced gastrointestinal disorders","volume":"5","author":"Philpott","year":"2014","journal-title":"Frontline Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jgh.13024","article-title":"Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics","volume":"31","author":"Toya","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.joa.2014.02.011","article-title":"Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation","volume":"30","author":"Yamashita","year":"2014","journal-title":"J. Arrythm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2020.08.032","article-title":"Adherence to dabigatran and the influence of dabigatran-induced gastrointestinal discomfort in the real-world practice","volume":"323","author":"Hwang","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9923772","DOI":"10.1155\/cdr\/9923772","article-title":"Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis","volume":"2025","author":"Oh","year":"2025","journal-title":"Cardiovasc. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: A nationwide cohort study","volume":"6","author":"Rutherford","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40256-024-00664-2","article-title":"Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data","volume":"24","author":"Mandt","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MEJ.0000000000001065","article-title":"Diagnosis and practical management of digoxin toxicity: A narrative review and consensus","volume":"30","author":"Andrews","year":"2023","journal-title":"Eur. J. Emerg. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: A real-world study base on FAERS database","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MCG.0000000000000432","article-title":"NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians","volume":"50","author":"Scheiman","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_46","unstructured":"(2025, July 11). FDA\u2019s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems, Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-Glycoprotein Transport System and Cardiovascular Drugs","volume":"61","author":"Mendell","year":"2013","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:02Z","timestamp":1760035022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ph18091311"],"URL":"https:\/\/doi.org\/10.3390\/ph18091311","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}